Piper Sandler Boosts Bausch Health Companies (NYSE:BHC) Price Target to $9.00

Bausch Health Companies (NYSE:BHC) had its target price lifted by Piper Sandler from $7.00 to $9.00 in a research note released on Monday morning, BayStreet.CA reports. They currently have a neutral rating on the stock.

A number of other research analysts also recently issued reports on the company. Jefferies Financial Group cut their price objective on Bausch Health Companies from $16.00 to $14.00 and set a buy rating for the company in a research note on Tuesday, February 20th. StockNews.com raised shares of Bausch Health Companies from a hold rating to a buy rating in a report on Wednesday, February 7th. Finally, Royal Bank of Canada decreased their price target on Bausch Health Companies from $12.00 to $11.00 and set a sector perform rating on the stock in a report on Tuesday, April 23rd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Hold and an average target price of $11.33.

Bausch Health Companies Trading Down 0.2 %

Shares of NYSE:BHC opened at $8.74 on Monday. Bausch Health Companies has a 12-month low of $5.57 and a 12-month high of $11.46. The stock has a market capitalization of $3.19 billion, a price-to-earnings ratio of -5.40 and a beta of 0.85. The stock has a fifty day simple moving average of $9.31 and a two-hundred day simple moving average of $8.20.

Bausch Health Companies (NYSE:BHC) last announced its earnings results on Thursday, February 22nd. The company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.14. The business had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Bausch Health Companies had a negative net margin of 6.76% and a positive return on equity of 5,147.48%. The firm’s revenue was up 9.8% on a year-over-year basis. During the same period in the prior year, the company earned $1.02 earnings per share. As a group, equities research analysts predict that Bausch Health Companies will post 3.95 EPS for the current year.

Institutional Investors Weigh In On Bausch Health Companies

A number of hedge funds have recently made changes to their positions in the company. Pinnacle Associates Ltd. grew its position in Bausch Health Companies by 14.1% in the first quarter. Pinnacle Associates Ltd. now owns 33,649 shares of the company’s stock worth $357,000 after acquiring an additional 4,149 shares in the last quarter. Range Financial Group LLC lifted its stake in shares of Bausch Health Companies by 9.3% during the 1st quarter. Range Financial Group LLC now owns 88,415 shares of the company’s stock worth $938,000 after acquiring an additional 7,514 shares during the last quarter. Salem Investment Counselors Inc. bought a new stake in shares of Bausch Health Companies during the first quarter worth $32,000. Vanguard Group Inc. grew its holdings in shares of Bausch Health Companies by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 11,599,131 shares of the company’s stock worth $93,025,000 after purchasing an additional 111,363 shares during the last quarter. Finally, Readystate Asset Management LP bought a new stake in shares of Bausch Health Companies during the fourth quarter valued at approximately $2,933,000. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.